Patent: 5,298,422
✉ Email this page to a colleague
Summary for Patent: 5,298,422
| Title: | Myogenic vector systems |
| Abstract: | The present invention includes a Myogenic vector system (MVS) for the expression of a nucleic acid sequence in myogenic tissue. The MVS contains a promoter, a cassette with the sequence of interest, a 3\' untranslated region (3\' UTR) and contiguous noncoding region (NCR). Further enhancements can include the addition of a leader sequence, intron sequence, initiation codon and specific This invention was partially supported by a grant from the United States government under HL-38401 awarded by the National Institute of Health. The Government has certain rights in the invention. |
| Inventor(s): | Schwartz; Robert J. (Houston, TX), DeMayo; Franco J. (Houston, TX), O\'Malley; Bert W. (Houston, TX) |
| Assignee: | Baylor College of Medicine (Houston, TX) |
| Application Number: | 07/789,919 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,298,422
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-02-26 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
